Cytarabine Valyl ester Hydrochloride

盐酸阿糖胞苷缬氨酸酯

Report date: 2022/12/07 17:16:02
NME

Base Information

Drug NameCytarabine Valyl ester Hydrochloride
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsLymphomaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenyang Pharmaceutical University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenyang Pharmaceutical UniversityKunming Jida Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A